Skip to search formSkip to main contentSkip to account menu

CGP 62221

Known as: CGP62221 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Staurosporine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia…
2017
2017
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug
The absorption, metabolism, and excretion of midostaurin, a potent class III tyrosine protein kinase inhibitor for acute… 
2016
2016
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multikinase… 
2013
2013
Evaluation of the effects of the PKC412-metabolites CGP52421 and CGP62221 on proliferation and viability of neoplastic mast cells and IgE dependent secretion of histamine
2012
2012
Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A…
Abstract 4913 Background: Among tyrosine kinase inhibitors, midostaurin (PKC412) takes place in the treatment of patients… 
Review
2009
Review
2009
Midostaurin: Review of pharmacokinetics (PK) and PK/pharmacodynamic (PD) relationship in AML/MDS patients.
e14540 Background: Midostaurin is a multi-tyrosine-kinases inhibitor targeting class III tyrosine-protein-kinases, including Fms… 
2008
2008
Dose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus
Midostaurin is a novel potent inhibitor of both protein kinase C and the major receptor for vascular endothelial growth factor… 
2008
2008
A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects
AbstractBackground and objective: Midostaurin, a novel potent inhibitor of protein kinase C enzyme and class III receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)